Search
Displaying 501–510 of 896 results for “vision connection”
-
4DMT Planning Phase 3 Clinical Trial for Wet AMD Gene Therapy
Research NewsKnown as 4D-150, the wet AMD gene therapy performed well in a Phase 2b clinical trial.
-
The Cincy Source provides a platform for professionals serving the blind and low vision community in Cincinnati and surrounding areas to showcase services and other resources.
-
Foundation Forums for Blindness
The Foundation Forums for Blindness is a network of professionals serving the blind and low vision community in markets all over the U.S.
-
GoodMaps and Be My Eyes.
-
Atsena’s XLRS Gene Therapy Shows Efficacy in Phase 1/2 Clinical Trial
Research NewsThe XLRS gene therapy was well tolerated and resolved damaging schisis cavities in patients receiving the lowest dose.
-
ViGeneron Launches Clinical Trial of Gene Therapy for RP Caused by CNGA1 Mutations
Research NewsThe gene therapy is administered using a less-invasive intravitreal injection.
-
Foundation News
Collaboration will add a new multi-gene cohort of patients living with inherited retinal diseases. Data insights from the new study cohort will inform the future clinical trial design for BlueRock’s pipeline of cell therapies for treating blindness.
-
Beacon Stories
Adopted into a musical family, Miles Hoyt picked up a guitar at just four years old, and he hasn’t stopped playing since. Now Miles, who has Stargardt disease, and his parents are using music to bring their community together to raise funds for blinding diseases with their Raising Our Sights fundraiser, Smiles for Miles.
-
Foundation News
The May 9th gala will raise awareness and fund research leading to treatments and cures for blinding retinal diseases.
-
Foundation’s Reach Inspires Partnership for Nixon Family
Beacon StoriesAfter Janine’s diagnosis of an IRD caused by a mutation of the PRPH2 gene, she and her husband set out to learn and help all they could. So they started working with the Foundation Fighting Blindness and have launched the ‘PRPH2 and Associated Retinal Degenerations Program.’
